Ostrava

• Sarilumab efficacy and safety in adults with early polymyalgia rheumatica Pending
  2024-511296-15-00 5 Musculoskeletal diseases
• A Phase II Open Label Study of Brentuximab Vedotin in Combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral … Pending
  2024-511567-28-01 4 Cancer
• Catheter-directed thrombolysis in intermediate-high risk acute pulmonary embolism Pending
  2024-516144-25-00 6 intermediate-high risk acute pulmonary embolism
• A phase 2 study of ianalumab in adults with primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) who … Pending
  2024-518231-11-00 4 Immune thrombocytopenia (ITP) Warm autoimmune hemolytic anemia (wAIHA
• Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infe … Pending
  2024-518420-80-00 5 Primary infection prophylaxis for secondary immunodeficiency (SID) in
• EdoxabaN foR IntraCranial Hemorrhage survivors with Atrial Fibrillation Pending
  2024-518508-31-00 6 High risk atrial fibrillation patients with previous intracranial hemo
• A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens … Pending
  2024-519504-27-00 5 Relapsed Refractory Multiple Myeloma
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• Study to assess the efficacy and safety of Rina-S plus standard of care compared to standard of care for maintenance treatment of participan … Pending
  2025-522167-15-00 5 Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)
• LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 Pending
  2025-522475-28-00 5 Pulmonary Hypertension (PH) with Heart Failure with preserved left ven
• A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell L … Pending
  2025-522818-23-00 5 Small Cell Lung Cancer (SCLC)
• Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) Pending
  2025-523389-26-00 5 Relapsed/refractory primary central nervous system lymphoma
• A study of pelabresib and ruxolitinib compared to placebo and ruxolitinib in adult patients with myelofibrosis who have not received prior t … Pending
  2025-523555-66-00 5 Myelofibrosis
• Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis Pending
  2025-523793-16-00 4 Homeostatic iron regulator gene-related hereditary hemochromatosis
• A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma Pending
  2025-523815-12-00 5 Relapsed or Refractory Multiple Myeloma
• Comparison of weekly Somatrogon to daily Genotropin in children born small for gestational age or with idiopathic short stature. Pending
  2025-523832-38-00 5 Small for gestational age (SGA) and idiopathic short stature (ISS)
• A phase 3 study of orelabrutinib in combination with rituximab plus bendamustine (BR) compared with BR in subjects with treatment-naїve mant … Pending
  2025-524241-27-00 5 Treatment-naїve mantle cell lymphoma (MCL)
• Low-dose versus standard-dose anticoagulation with argatroban or enoxaparin during extracorporeal membrane oxygenation controlled by anti-II … Pending
  2025-524553-13-00 4 lung and/or heart failure
• A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003) Recruiting
  2025-524894-17-00 10 2026-06-22 Neovascular age-related macular degeneration (NVAMD)
• A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Recruiting
  2025-523586-18-00 5 2026-06-11 Non-Small Cell Lung Cancer
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Recruiting
  2025-521590-13-00 5 2026-05-28 Moderately to Severely Active Crohn’s Disease
• MAVRiC studies 2L treatment with AV in patients with CLL/SLL who have relapsed after a course of BTKi + BCL2i combination, with and without … Recruiting
  2024-518858-17-00 4 2026-05-22 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
• A Global Study Testing the New Drug Olverembatinib combined with chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Pos … Recruiting
  2024-511496-14-00 5 2026-05-14 Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)

Showing 1–24 of 249 trials